jm1c00541_si_007.pdb (338.86 kB)
Download fileDevelopment of Novel Glucocorticoids for Use in Antibody–Drug Conjugates for the Treatment of Inflammatory Diseases
dataset
posted on 11.08.2021, 15:07 authored by Amy Han, Olav Olsen, Christopher D’Souza, Jing Shan, Feng Zhao, Jean Yanolatos, Zaruhi Hovhannisyan, Sokol Haxhinasto, Frank Delfino, William OlsonGlucocorticoids
(GCs) are widely used to treat a variety of autoimmune
and inflammatory diseases; however, systemic delivery of GCs is associated
with side effects that affect essentially every organ system, reflecting
the nearly ubiquitous expression of the glucocorticoid receptor (GR).
Targeted delivery of GCs to diseased tissues using antibody-glucocorticoid
conjugates (GC-ADCs) offers a therapeutic alternative to overcome
these adverse effects. Herein, we describe novel classes of GCs that
exhibited greater potency than dexamethasone and budesonide, a 100-fold
selectivity toward the GR over other nuclear receptors, and no in vitro safety liability in pharmacology assays (hERG,
AMES) and that demonstrated a substantial reduction in tumor necrosis
factor-α (TNF-α) release in mice challenged with lipopolysaccharide
(LPS). The site-specific conjugated GC-ADCs via cathepsin-cleavable
linkers were highly stable in plasma and specifically released GCs
in antigen-positive cells, suggesting that these novel GCs can serve
as ADC payloads to treat autoimmune and inflammatory diseases.
History
Usage metrics
Read the peer-reviewed publication
Categories
Keywords
cathepsin-cleavable linkersADC payloadsTargeted deliverynovel GCsAMEStumor necrosis factor -αpharmacology assaysorgan systemsafety liabilityGRLPSside effectsInflammatory Diseases Glucocorticoidsglucocorticoid receptornovel classesGC-ADCantigen-positive cellsantibody-glucocorticoid conjugatesTNFNovel Glucocorticoids